Enhanced external counterpulsation for ischemic heart disease What’s behind the curtain? by Bonetti, Piero O et al.
STATE-OF-THE-ART PAPER
Enhanced External Counterpulsation
for Ischemic Heart Disease
What’s Behind the Curtain?
Piero O. Bonetti, MD, David R. Holmes, JR, MD, FACC, Amir Lerman, MD, FACC,
Gregory W. Barsness, MD, FACC
Rochester, Minnesota
Enhanced external counterpulsation (EECP) has been shown to reduce angina and to
improve objective measures of myocardial ischemia in patients with refractory angina.
Prospective clinical studies and large treatment registries suggest that a course of EECP is
associated with prolongation of the time to exercise-induced ST-segment depression and
resolution of myocardial perfusion defects, as well as with enhanced exercise tolerance and
quality of life. With a growing knowledge base supporting the safety and beneficial clinical
effects associated with EECP, this therapy can be considered a valuable treatment option,
particularly in patients who have exhausted traditional revascularization methods and yet
remain symptomatic despite optimal medical care. However, although the concept of external
counterpulsation was introduced almost four decades ago, and despite growing evidence
supporting the clinical benefit and safety of this therapeutic modality, little is firmly
established regarding the mechanisms responsible for the beneficial effects associated with this
technique. Suggested mechanisms contributing to the clinical benefit of EECP include
improvement in endothelial function, promotion of coronary collateralization, enhancement
of ventricular function, peripheral effects similar to those observed with regular physical
exercise, and nonspecific placebo effects. This review summarizes the current evidence for a
contribution of these mechanisms to the clinical benefit associated with EECP. (J Am Coll
Cardiol 2003;41:1918–25) © 2003 by the American College of Cardiology Foundation
An estimated 6.4 million patients in the U.S. suffer from
symptomatic coronary artery disease (CAD), and about
400,000 new cases develop each year (1). As more patients
survive a primary coronary event, this number will likely
continue to grow, as will the cohort of patients who remain
symptomatic despite optimal medical therapy. Unfortu-
nately, a considerable segment of this population is not
amenable to standard revascularization procedures, such as
percutaneous coronary intervention and coronary artery
bypass graft surgery, because of unsuitable coronary anat-
omy, multiple previous revascularization attempts, or addi-
tional comorbid conditions. Currently, several alternative
therapeutic options are available for patients with refractory
angina, including neurostimulation (transcutaneous electri-
cal nerve stimulation and spinal cord stimulation), laser
revascularization techniques, and enhanced external coun-
terpulsation (EECP) (2). Of these modalities, EECP rep-
resents the only truly noninvasive technique for which both
a reduction of anginal symptoms and an improvement in
objective measures of myocardial ischemia have been shown.
Several small trials demonstrated a consistently positive
clinical response among patients treated with EECP (Table
1). Benefits associated with EECP include reduction of
angina (3–9) and nitrate use (5,6,8), increased exercise
tolerance (5,7,9–12), favorable psychosocial effects and
enhanced quality of life (13,14), as well as prolongation of
the time to exercise-induced ST-segment depression
(10,12) and an accompanying resolution of myocardial
perfusion defects (5–12). The randomized, double-blinded,
sham-controlled Multicenter Study of Enhanced External
Counterpulsation (MUST-EECP) documented the clinical
benefit of EECP in patients with chronic stable angina and
positive exercise stress tests (Table 2) (15). Moreover, a
MUST-EECP substudy demonstrated a significant im-
provement in quality of life parameters in patients assigned
to active treatment, which was sustained during a 12-month
follow-up period (16). Results from the International
EECP Patient Registry (IEPR) (17) and the EECP Clin-
ical Consortium (18) have demonstrated that the symptom-
atic benefit observed in controlled studies also translates to
the heterogeneous patient population seen in clinical prac-
tice. Moreover, follow-up data indicate that the clinical
benefit may be maintained for up to five years in patients
with a favorable initial clinical response (8,17,19).
Despite the growing body of evidence supporting the
clinical benefit of EECP therapy in patients with chronic
angina, the mechanisms by which this technique improves
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symptoms are poorly understood. By reviewing the currently
available literature, this article summarizes the mechanisms
potentially responsible for the clinical benefit observed with
EECP.
Principles and hemodynamic effects of EECP. A stan-
dard EECP treatment course comprises 35 one-hour ses-
sions over a seven-week period. Three pairs of pneumatic
cuffs, wrapped around the calves, lower thighs, and upper
thighs are sequentially inflated with compressed air from
distal to proximal in early diastole and rapidly deflated at the
onset of systole (Fig. 1). Analogous to intraaortic balloon
counterpulsation, the rapid inflation raises diastolic pressure
(diastolic augmentation) while the rapid cuff deflation pro-
motes lower extremity arterial “runoff” and leads to a
decrease in systolic pressure (systolic unloading) in both the
aorta and the coronary arteries (20). Unlike intraaortic
balloon counterpulsation, EECP also enhances venous re-
turn, further promoting an increase in cardiac output (21).
These hemodynamic effects lead to increased blood flow in
multiple vascular beds, including the coronary arterial cir-
culation (Table 3) (20,22).
The magnitude of EECP-associated hemodynamic
changes can be estimated noninvasively by measuring the
diastolic to systolic effectiveness ratio using finger plethys-
mography (peak diastolic amplitude divided by the peak
systolic amplitude) (Fig. 2). Doppler echocardiographic
studies during application of EECP indicate that an effec-
tiveness ratio of 1.5 to 2 is associated with an optimal
increase in both systolic antegrade and diastolic retrograde
aortic flow (23). However, given that a considerable pro-
portion of patients who derive symptomatic benefit do not
achieve an effectiveness ratio of 1.5 to 2, the clinical
significance of this finding is unclear (3,24,25).
Effect on endothelial function. The endothelium plays a
crucial role in vascular homeostasis (26). Whereas normal
endothelial function is characterized by atheroprotective
properties, endothelial dysfunction is now considered an
early step in atherogenesis (27,28). Endothelial dysfunction
is characterized by impaired bioavailability of endothelium-
derived nitric oxide (NO), which has vasodilatory, antiplate-
let, antithrombotic, antiproliferative, and anti-inflammatory
properties. However, endothelial production of the major
opponent of NO, endothelin-1, a potent vasoconstrictor
that also exerts prothrombotic, mitogenic, and proinflam-
matory effects, is increased in the setting of endothelial
dysfunction (29). This imbalance between vasodilators and
vasoconstrictors leads to an impairment of endothelium-
dependent vasodilation, which represents the functional
characteristic of endothelial dysfunction. Importantly, the
presence of coronary endothelial dysfunction is associated
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
CAD  coronary artery disease
EECP  enhanced external counterpulsation
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IEPR  International Enhanced External
Counterpulsation Patient Registry
LV  left ventricular
LVEF  left ventricular ejection fraction
MUST-EECP  Multicenter Study of Enhanced
External Counterpulsation
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Table 1. Published Controlled and Uncontrolled Trials of Enhanced External Counterpulsation in Patients With Stable Angina
Study (Ref.) Year n
Treatment
Duration
(h)
Angina
(% >1 CCS
Class)*
Nitrate
Use
Exercise
Tolerance
(%)*
Time to ST
Depression
Cardiac
Perfusion
(%)*
Zheng et al. (4) 1983 200 12 2 (97) N/A N/A N/A N/A
Lawson et al. (5) 1992 18 36 2 (100) 2 1 (67) N/A 1 (78)
Lawson et al. (11) 1996 27 35 N/A N/A 1 (81) N/A 1 (78)
Lawson et al. (6) 1996 50 35 2 (100) 2 N/A N/A 1 (80)
Lawson et al. (7) 1998 60 35 2 N/A 1 N/A 1 (75)
Arora et al. (15) 1999 139 35 2 2 1 1 N/A
Lawson et al. (8) 2000 33 35–36 2 (100) 2 N/A N/A 1 (79)
Lawson et al. (18) 2000 2,289 35 2 (74) N/A N/A N/A N/A
Urano et al. (12) 2001 12 35 N/A N/A 1 1 1
Masuda et al. (10) 2001 11 35 N/A N/A 1 1 1
Stys et al. (3) 2001 395 35 2 (88) N/A N/A N/A N/A
Barsness et al. (17) 2001 978 35 2 (81) 2 N/A N/A N/A
Stys et al. (9) 2002 175 35 2 (85) N/A 1 N/A 1 (83)
*When reported in the original article, the percentage of patients for whom the criterion applies are listed in parentheses.
CCS  Canadian Cardiovascular Society; N/A  not assessed.
Table 2. Effect of EECP on Subjective and Objective
Parameters of Myocardial Ischemia in the Multicenter Study of
Enhanced External Counterpulsation (MUST-EECP) (15)
Active EECP Sham-EECP p Value
Change from baseline in
angina count per day
0.033  0.27 0.15  0.27  0.05
Change in time to
exercise-induced
1-mm ST-segment
depression (s)
37  11 4  12 0.01
EECP  enhanced external counterpulsation.
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with myocardial ischemia and an adverse prognosis irrespec-
tive of the presence of obstructive coronary lesions (28).
Growing evidence suggests that improvement in endo-
thelial function represents an important mechanism for the
clinical benefit observed with EECP. Central to this con-
cept is the increase in organ blood flow observed during
treatment (20,22). In the absence of significant vascular
obstruction, EECP-induced increases in blood flow translate
into enhanced endothelial shear stress (30,31). Increased shear
stress represents a major stimulus for endothelial NO release
Figure 1. Principle of enhanced external counterpulsation. Three pairs of pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs.
During early diastole, these cuffs are inflated sequentially from distal to proximal, resulting in a “milking effect” of blood from the lower extremities. At the
onset of systole, all cuffs are deflated, resulting in acute afterload reduction. Modified from the October 2001 Mayo Clinic Health Letter. Copyright Mayo
Foundation for Medical Education and Research. All rights reserved. Used with permission.
Table 3. Effect of Enhanced External Counterpulsation on Blood Flow in Different Vascular Beds
Study (Ref.) Cuff Location Applied Pressure Vessel Method
Flow
Change
Werner et al. (22) Calves, lower thighs 200 mm Hg Carotid artery Duplex 19%
Calves, lower thighs 200 mm Hg Vertebral artery Duplex 12%
Calves, lower thighs 200 mm Hg Hepatic artery Duplex 25%
Calves, lower thighs 200 mm Hg Renal artery Duplex 21%
Calves, lower thighs 200 mm Hg Abdominal aorta Duplex 88%
Calves, lower thighs 200 mm Hg Internal iliac artery Duplex 144%
Calves, lower thighs 200 mm Hg Left coronary main stem Transesophageal Doppler
echocardiography
18%
Calves, lower 
upper thighs
300 mm Hg Carotid artery Duplex 26%
Calves, lower 
upper thighs
300 mm Hg Left coronary main stem Transesophageal Doppler
echocardiography
42%
Michaels et al. (20) Calves, lower 
upper thighs
100–300 mm Hg Left or right coronary artery Intracoronary Doppler 109%
Calves, lower 
upper thighs
100–300 mm Hg Left or right coronary artery Corrected TIMI frame count 28%
TIMI  Thrombolysis In Myocardial Infarction.
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and vasodilation (32–34). Shear stress also modulates endothe-
lial endothelin-1 release, as sustained exposure of the endothe-
lium to low levels of shear stress stimulates endothelin-1
release, whereas longer exposure to higher shear stress levels is
associated with a reduction of endothelial endothelin-1 release
(34,35). Therefore, an appropriate level of shear stress is
considered a key factor for the maintenance of a functional
endothelium (36,37).
Given this important role of shear stress for endothelial
homeostasis, it seems plausible that EECP, by enhancing
vascular shear stress, may favorably affect endothelial func-
tion. Supporting this presumption, a significant increase in
plasma NO levels was found one month following comple-
tion of a course of EECP in patients with CAD (38). In
another study, EECP was associated with a significant and
dose-related increase in plasma NO levels in patients with
CAD whose baseline NO levels were significantly lower
than those of healthy controls. Most strikingly, by the end
of treatment, average NO levels in treated patients had risen
to levels comparable to those measured in the control group
(21). Similarly, it was demonstrated that a course of EECP
was associated with a significant increase in plasma NO
levels and a significant decrease in plasma endothelin-1
levels in patients with CAD. These changes of plasma NO
and endothelin-1 levels were in proportion to treatment
duration, and these changes from baseline persisted one
month after completion of EECP (21).
Enhanced external counterpulsation may also affect oxi-
dative stress, which is associated with various cardiovascular
risk factors and is considered a key factor in the develop-
ment of endothelial dysfunction and atherosclerosis (39). In
patients with CAD, EECP was shown to be associated with
a linear decrease in plasma markers of oxidative stress in
proportion to the number of hours of treatment (21).
Although the exact mechanism for the reduction of oxida-
tive stress observed in this study is not clear, it has been
shown that reactive oxygen species and NO interact chem-
ically to neutralize each other. It can therefore be speculated
that improved endothelial function and increased NO
bioavailability with EECP may reduce oxidative stress.
Preliminary data also indicate that EECP may decrease
plasma angiotensin II levels in patients with CAD (40).
Thus, given the promoting effect of angiotensin II on
vascular superoxide production (41), EECP-induced lower-
ing of angiotensin II levels might also contribute to a
decrease in oxidative stress.
Indirect evidence for the existence of a beneficial effect of
EECP on endothelial function stems from the observation
that the level of diastolic augmentation, or the effectiveness
ratio, tends to increase over the course of treatment (3,25).
The magnitude of the effectiveness ratio achieved during
EECP depends not only on device-related factors, such as
cuff inflation pressure and timing of inflation/deflation
sequence, but also on individual patient-dependent param-
eters, including arterial stiffness. An increase in arterial
stiffness leads to systolic pressure elevation and, therefore,
decreases the effectiveness ratio. Arterial stiffness is influ-
enced by the functional status of the arterial wall including
the bioavailability of endothelium-derived NO. Indeed,
endothelial dysfunction is associated with increased arterial
stiffness (42). Thus, it can be speculated that an improve-
ment in the effectiveness ratio during EECP mirrors im-
provement in endothelial function. In line with this hypoth-
esis, recent data of 2,486 patients from the IEPR indicate
that patients whose effectiveness ratio improves over the
course of treatment also tend to experience the greatest
reduction in angina class up to six months after treatment
(25), supporting the notion that improvement in endothelial
function may, indeed, contribute to the clinical benefit
observed with EECP.
Taken together, these indirect findings suggest a desirable
effect of EECP on endothelial function. However, further
studies to address the effect of EECP on well-established
parameters of endothelial function, such as endothelium-
dependent vasodilation, are required to more specifically
define the impact of EECP on endothelial function.
Effect on coronary collateral supply. Enhancement of
collateral perfusion involves opening or expansion of pre-
Figure 2. Electrocardiogram (upper panel) and finger plethysmographic recording (lower panel) after initiation of enhanced external counterpulsation
(EECP). Enhanced external counterpulsation leads to an increase in diastolic pressure (diastolic augmentation) and a decrease in systolic pressure (systolic
unloading). The magnitude of EECP-induced hemodynamic changes is commonly assessed by measuring the diastolic-to-systolic effectiveness ratio, which
is calculated by dividing the peak diastolic amplitude by the peak systolic amplitude of the finger plethysmographic signal.
1921JACC Vol. 41, No. 11, 2003 Bonetti et al.
June 4, 2003:1918–25 Enhanced External Counterpulsation
formed collaterals as well as formation of new collateral
vessels. Aside from ischemia, an increase in endothelial
shear stress is considered a major stimulus for collateral
development and recruitment (43), underlying the hypoth-
esis that EECP may exert its beneficial effects at least in part
by enhancement of coronary collateralization through de-
velopment of these shear forces.
The simplest mechanism by which EECP might increase
collateral perfusion is by opening preformed collateral chan-
nels, either directly via increasing diastolic blood pressure
and flow or indirectly via release of vasodilatory mediators
such as NO, as discussed earlier. Canine studies have shown
an acute, significant increase in the patency of hind limb
collateral and anastomotic branches in response to 1 h of
external counterpulsation (44) and acute enhancement of
capillary density in experimental myocardial infarction
treated with external counterpulsation (21). The translation
of these findings to the situation in humans, however, is
limited by the fact that collaterals develop much faster in
dogs than in humans.
Similarly, the shear forces induced by EECP may influ-
ence arteriogenesis and angiogenesis. Arteriogenesis, the
formation of larger collateral arteries via the addition of
endothelial cells, smooth muscle cells, fibroblasts, and con-
nective tissue to preexisting collateral arterioles, represents
another mechanism involved in the enhancement of coro-
nary collaterals (45). The primary initiating stimulus for this
vascular remodeling process is felt to be an increase in shear
stress (44), making arteriogenesis an attractive mechanism
by which EECP might improve myocardial perfusion.
Angiogenesis, the de novo formation of capillary blood
vessels via sprouting of endothelial cells from existing blood
vessels, may also be promoted by EECP. Angiogenesis is a
complex process that depends on a well-coordinated inter-
play of a myriad of vascular-specific and -nonspecific factors
(46). Notably, vascular shear stress may upregulate endo-
thelial production of growth factors (such as vascular endo-
thelial growth factor [VEGF] and platelet-derived growth
factor) that are crucial for the proper sequence of angiogen-
esis (47,48). In this way, shear stress may also be an
important player in the angiogenic process.
Indirect evidence for the existence of a pro-arteriogenic
and pro-angiogenic effect of EECP stems from studies
showing an increase in various vascular growth factors in
response to treatment. A significant increase in plasma
VEGF levels was reported in five patients with refractory
angina who experienced a 50% reduction in anginal episodes
after a course of EECP, whereas no change in plasma
VEGF concentration was found in four patients whose
symptoms did not respond to EECP (21). Furthermore, in
11 patients with stable angina, an increase in plasma levels
of basic fibroblast growth factor, VEGF, and hepatocyte
growth factor (HGF) was demonstrated after a course of
EECP (49). Interestingly, HGF is a very potent angiogenic
factor that shows a greater angiogenic potential than VEGF
(50).
A link between vasodilation and angiogenesis is suggested
by the observation that in vivo angiogenesis is accompanied
by vasodilation and that several angiogenic factors have
vasodilating properties (51). For example, VEGF was
shown to enhance endothelial nitric oxide synthase expres-
sion and activity (52–54), stimulating NO-dependent vaso-
dilation (55). On the other hand, endothelial NO produc-
tion is crucial for the stimulatory effect of VEGF on the
growth of endothelial cells and their organization in
network-like structures (53). The strongest evidence for a
pivotal role of NO in the angiogenic process stems from a
study investigating the angiogenic response in a murine
model of hindlimb ischemia (56). In this study, angiogen-
esis in the ischemic hindlimb was significantly impaired in
mice with targeted disruption of the gene encoding endo-
thelial nitric oxide synthase as compared with wild-type
controls. These results indicate that NO represents a crucial
cofactor for angiogenesis. Thus, it can be speculated that
disease states associated with a decrease in NO bioavailabil-
ity, such as endothelial dysfunction, may limit angiogenesis,
whereas interventions that improve endothelial function
may promote angiogenesis.
Vasculogenesis, the in situ formation of blood vessels
involving bone marrow-derived endothelial progenitor cells,
was recently described as an additional mechanism that may
contribute to collateral development (57). Aside from cer-
tain cytokines or tissue ischemia (58), VEGF may promote
endothelial progenitor cell mobilization and differentiation
in vivo (59,60). Given the increase in plasma VEGF levels
observed in some EECP-treated patients, it can be hypoth-
esized that vasculogenesis might also be a mechanism by
which EECP promotes collateral development in certain
patients with CAD.
In summary, these findings suggest a potential for EECP
to enhance coronary collateralization. Moreover, it appears
that the presumed effect of EECP on endothelial function
might further increase the pro-angiogenic potential of this
technique. However, an increase in plasma levels of various
angiogenic growth factors does not necessarily translate into
enhanced coronary collateralization, and there is still little
direct evidence for a stimulating effect of EECP on cardiac
collateral formation. Thus, further studies are necessary to
define the exact role of neovascularization for the beneficial
effect of EECP.
Peripheral effect. The question whether EECP is associ-
ated with a nonspecific peripheral “training effect” was
studied in 27 patients with chronic stable angina who
underwent a maximal stress test before and after a course of
EECP (11). After treatment a significant increase in exer-
cise duration was noted in these patients, while peak double
product remained unchanged, which was due mainly to a
distinct, although not statistically significant, reduction in
maximal blood pressure. Similar findings were reported in
175 patients with chronic stable angina who underwent a
baseline exercise stress test before EECP treatment and
either a maximal exercise stress test or an exercise stress test
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to the same level as before treatment within six months after
completion of EECP therapy (9). In this study, patients
who underwent maximal post-EECP exercise stress testing
showed a significant improvement in exercise duration with
no change in peak double product, whereas the same
exercise level as before EECP was achieved with a signifi-
cantly lower double product, supporting the notion that
EECP, similar to physical training, may promote a decrease
in peripheral vascular resistance.
Using positron emission tomography, it was found that a
course of EECP improved myocardial perfusion, both at
rest and in response to dipyridamole, in 11 patients with
CAD (38). However, maximal exercise stress tests before
and after EECP showed a similar peak double product,
despite a significant increase in time to 1-mm ST-segment
depression and a trend towards longer total exercise time,
suggesting that the increase in exercise tolerance found in
these patients was partly due to a peripheral effect of EECP.
These data suggest the importance of both an improve-
ment in myocardial perfusion and a decrease in peripheral
resistance in achieving the clinical benefit associated with
EECP. Peripheral effects might be particularly important
for the symptomatic improvement observed in patients
without evidence for enhanced myocardial perfusion after
EECP.
Effect on ventricular function. By reducing afterload and
promoting venous return, EECP acutely enhances cardiac
output up to 25% (61,62). However, the venous return
augmentation by EECP has also raised concerns about the
possibility of inducing pulmonary edema in patients with
impaired left ventricular (LV) function and heart failure. To
date, little is known about the effect of EECP in patients
with impaired LV function or heart failure, although this
procedure was recently granted FDA approval for the
treatment of patients with angina and accompanying heart
failure. Evidence supporting a beneficial effect of EECP on
ventricular function includes an uncontrolled study demon-
strating a significant reduction of atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP) plasma levels in
response to a course of EECP in 11 patients with stable
angina (10). A similar reduction in plasma levels of BNP but
not ANP was found in 12 patients with refractory stable
angina and normal LV ejection fraction (LVEF) after 35 h
of EECP (12). Treatment did not alter systolic LV function
but significantly improved parameters of diastolic ventricu-
lar function, indicating a role for EECP in the treatment of
patients with predominant or isolated diastolic ventricular
dysfunction. The effect of EECP on LV systolic function
was investigated in eight patients with severely impaired
LVEF (mean 25%) (63). After EECP therapy, these pa-
tients showed a significant increase in LVEF (to 29%),
which was accompanied by a significant decrease in resting
heart rate.
The presence of LV dysfunction does not appear to
Figure 3. Possible mechanisms responsible for the clinical benefit associated with enhanced external counterpulsation (EECP). Acute afterload reduction
decreases myocardial demand. By increasing coronary blood flow, EECP is thought to promote myocardial collateralization via opening of preformed
collaterals, arteriogenesis, and angiogenesis. Increased blood flow and shear stress may also improve coronary endothelial function favoring vasodilation and
myocardial perfusion. In addition, improvement in endothelial function may further promote collateral formation by arteriogenesis and angiogenesis.
Besides a peripheral training effect, a minor placebo effect is considered to contribute to the symptomatic benefit of EECP. ET  endothelin; NO  nitric
oxide.
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substantially impair clinical response to EECP in patients
with angina. In a pilot study assessing the effect and safety
of EECP in heart failure (64), 26 patients with either
idiopathic or ischemic heart failure (New York Heart
Association class II to III) and an average LVEF of 23%
experienced significantly improved exercise tolerance and
quality of life after a course of EECP, with no serious
adverse events. A retrospective IEPR analysis demonstrated
that 129 patients with a LVEF 35% before treatment
achieved similar reductions in angina compared with pa-
tients with preserved LV function (65).
In summary, current evidence suggests a positive effect of
EECP on both diastolic and systolic ventricular function.
Moreover, preliminary data indicate that EECP represents
an effective and safe treatment for stable patients with
impaired ventricular function. However, we still have to
await the results of larger ongoing trials investigating the
efficacy and safety of EECP in patients with heart failure
before this treatment can be definitively recommended for
treatment of this patient population.
Nonspecific placebo effects. The prolonged duration of
EECP treatment (seven weeks), and the fact that this
therapy is limited to specific centers where close medical
attention is provided, opens the possibility that nonspecific
factors may have a significant effect in reducing the symp-
toms of treated patients. Such factors include increased
patient compliance with drug treatment regimens and close
adherence to treatment guidelines among treating physi-
cians and interested practitioners. In addition, several lines
of evidence indicate that the use of medical devices may be
associated with an enhanced placebo effect (66).
The fact that many patients experience significant symp-
tomatic improvement, even in the absence of optimal
diastolic augmentation during treatment, indicates that a
placebo effect may indeed contribute to the symptomatic
benefit observed with EECP (3,23). Data from the random-
ized, sham-controlled MUST-EECP trial, however, sug-
gest that nonspecific factors, although possibly contributing
to the observed effects, are not the only determinants of the
clinical benefit observed with EECP (Table 2) (15).
Conclusions. Enhanced external counterpulsation is a
valuable outpatient procedure, providing acute and long-
term relief of anginal symptoms and improved quality of life
among a heterogeneous group of patients with symptomatic
ischemic heart disease. Recent evidence suggests that EECP
may improve symptoms via various mechanisms, including
improvement in endothelial function, promotion of collat-
eralization, enhancement of ventricular function, and pe-
ripheral effects similar to those observed in response to
regular physical exercise. In addition, nonspecific placebo
effects might contribute to the observed symptomatic ben-
efit (Fig. 3). However, most of this evidence is based on the
results of small, uncontrolled trials or on preliminary re-
ports. Therefore, controlled trials, including sham-EECP
control groups, are needed to further define the role of the
presumed mechanisms of action of EECP. Also, more has
to be learned about which patients benefit the most from
EECP treatment. Finally, the results of ongoing trials in
patients with impaired LV function will help define the role
of EECP as a therapeutic tool in this rapidly growing
patient population. At present, with a symptomatic benefit
documented in thousands of patients along with a favorable
safety profile, EECP can be considered a valuable treatment
option in patients with refractory angina.
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